MINK THERAPEUTICS INC

Explore Mink Therapeutics: a liquid, clinical‑stage biotech with a unique allogeneic iNKT therapy platform, poised for Q4 2026 data and solid investor support.

In a 24‑hour surge, Mink Therapeutics (INKT) jumped 7.71% as investors rally behind its iNKT cell therapy pipeline, beating peers and boosting market confidence.

Track Mink Therapeutics (INKT) stock: $9.86, 1.59% rise, 21.96% drop since last month. Learn its 52‑week range, market cap, and peer comparison.

Check Mink Therapeutics’ latest Nasdaq performance—$9.87, up 1.6% amid a volatile month— and discover its iNKT cell therapy potential for cancer and immune diseases.